{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T02:41:03Z","timestamp":1791600063832,"version":"4.3.4"},"reference-count":13,"publisher":"Oxford University Press (OUP)","issue":"Supplement_5","license":[{"start":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T00:00:00Z","timestamp":1773360000000},"content-version":"vor","delay-in-days":2,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>In the field of heart failure, sodium\u2013glucose cotransporter 2 inhibitors (SGLT2-i) have demonstrated robust efficacy and have received a Class I, Level A recommendation for reducing the risk of heart failure hospitalizations and cardiovascular mortality across the entire spectrum of left ventricular ejection fraction. The therapeutic effect occurs early, with the first statistical significance observed as soon as 12\u201328 days after treatment initiation. Evidence suggests that early introduction during hospitalization may reduce the short-term risk of cardiovascular death or worsening heart failure. SGLT2 inhibitors display a favourable safety and tolerability profile, without an increased incidence of adverse events compared with placebo. Furthermore, they are indicated for the treatment of type 2 diabetes mellitus and chronic kidney disease, irrespective of the presence of heart failure. Therefore, we propose that in patients presenting with signs and\/or symptoms of heart failure and elevated natriuretic peptide levels, SGLT2 inhibitors may be initiated even before echocardiographic confirmation of the diagnosis. Given the favourable risk\u2013benefit profile, this approach may help avoid therapeutic delay, which could otherwise be associated with an increased risk of early adverse events, and may ultimately improve prognosis.<\/jats:p>","DOI":"10.1093\/eurheartjsupp\/suag039","type":"journal-article","created":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T12:43:02Z","timestamp":1771936982000},"page":"v154-v158","source":"Crossref","is-referenced-by-count":2,"title":["Unexpected therapeutic scenarios: initiating SGLT2 inhibitors in de novo heart failure without echocardiography"],"prefix":"10.1093","volume":"28","author":[{"given":"Luca Antonio Felice","family":"Di Odoardo","sequence":"first","affiliation":[{"name":"Cardiovascular Department, ASST Papa Giovanni XXIII , Bergamo ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilia","family":"D\u2019Elia","sequence":"additional","affiliation":[{"name":"Cardiovascular Department, ASST Papa Giovanni XXIII , Bergamo ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edoardo","family":"Sciatti","sequence":"additional","affiliation":[{"name":"Cardiovascular Department, ASST Papa Giovanni XXIII , Bergamo ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ottavio","family":"Zucchetti","sequence":"additional","affiliation":[{"name":"Cardiovascular Department, ASST Papa Giovanni XXIII , Bergamo ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Fazzini","sequence":"additional","affiliation":[{"name":"Cardiovascular Department, ASST Papa Giovanni XXIII , Bergamo ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"D\u2019Isa","sequence":"additional","affiliation":[{"name":"Cardiovascular Department, ASST Papa Giovanni XXIII , Bergamo ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Senni","sequence":"additional","affiliation":[{"name":"Cardiovascular Department, ASST Papa Giovanni XXIII , Bergamo ,","place":["Italy"]},{"name":"School of Medicine and Surgery, University of Milan\u2013Bicocca , Milan ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,3,11]]},"reference":[{"key":"2026050607122178300_suag039-B1","doi-asserted-by":"crossref","first-page":"3272","DOI":"10.1093\/cvr\/cvac013","article-title":"Global burden of heart failure: a comprehensive and updated review of epidemiology","volume":"118","author":"Savarese","year":"2023","journal-title":"Cardiovasc Res"},{"key":"2026050607122178300_suag039-B2","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.cardfail.2021.01.022","article-title":"Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure","volume":"27","author":"Bozkurt","year":"2021","journal-title":"J Card Fail"},{"key":"2026050607122178300_suag039-B3","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1002\/ejhf.2149","article-title":"Rapid evidence-based sequencing of foundational drugs for heart failure and a reduced ejection fraction","volume":"23","author":"Packer","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026050607122178300_suag039-B4","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1016\/j.cardfail.2022.04.011","article-title":"Eligibility for dapagliflozin and empagliflozin in a real-world heart failure population","volume":"28","author":"Thorvaldsen","year":"2022","journal-title":"J Card Fail"},{"key":"2026050607122178300_suag039-B5","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1016\/j.amjmed.2023.04.019","article-title":"Chapter 3: clinical trials of sodium-glucose co-transporter-2 inhibitors for treatment of heart failure","volume":"137","author":"Greene","year":"2024","journal-title":"Am J Med"},{"key":"2026050607122178300_suag039-B6","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1038\/s41591-022-01971-4","article-title":"Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER","volume":"28","author":"Jhund","year":"2022","journal-title":"Nat Med"},{"key":"2026050607122178300_suag039-B7","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1093\/eurheartj\/ehab798","article-title":"Effect of empagliflozin in patients with heart failure across the spectrum of left ventricular ejection fraction","volume":"43","author":"Butler","year":"2022","journal-title":"Eur Heart J"},{"key":"2026050607122178300_suag039-B8","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1002\/ejhf.2397","article-title":"Sodium-glucose co-transporter 2 inhibitors as an early, first-line therapy in patients with heart failure and reduced ejection fraction","volume":"24","author":"Tomasoni","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"2026050607122178300_suag039-B9","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1093\/eurheartj\/ehaf034","article-title":"Suspected de novo heart failure in outpatient care: the REVOLUTION HF study","volume":"46","author":"Anderson","year":"2025","journal-title":"Eur Heart J"},{"key":"2026050607122178300_suag039-B10"},{"key":"2026050607122178300_suag039-B11","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehaf788","article-title":"Urinary tract infection and continuation of sodium-glucose cotransporter-2 inhibitors in diabetic patients","author":"Wu","year":"17  2025","journal-title":"Eur Heart J"},{"key":"2026050607122178300_suag039-B12","doi-asserted-by":"crossref","first-page":"i137","DOI":"10.1093\/eurheartjsupp\/suae117","article-title":"SGLT2 inhibitors and new frontiers in heart failure treatment regardless of ejection fraction and setting","volume":"27","author":"Merlo","year":"2025","journal-title":"Eur Heart J Suppl"},{"key":"2026050607122178300_suag039-B13","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1002\/ejhf.3646","article-title":"The use of left ventricular ejection fraction in the diagnosis and management of heart failure. A clinical consensus statement of the Heart Failure Association (HFA) of the ESC, the Heart Failure Society of America (HFSA), and the Japanese Heart Failure Society (JHFS)","volume":"27","author":"Rosano","year":"2025","journal-title":"Eur J Heart Fail"}],"container-title":["European Heart Journal Supplements"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurheartjsupp\/advance-article-pdf\/doi\/10.1093\/eurheartjsupp\/suag039\/67329982\/suag039.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurheartjsupp\/article-pdf\/28\/Supplement_5\/v154\/67329982\/suag039.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurheartjsupp\/article-pdf\/28\/Supplement_5\/v154\/67329982\/suag039.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T11:12:30Z","timestamp":1778065950000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartjsupp\/article\/28\/Supplement_5\/v154\/8518120"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,11]]},"references-count":13,"journal-issue":{"issue":"Supplement_5","published-online":{"date-parts":[[2026,3,11]]},"published-print":{"date-parts":[[2026,5,6]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartjsupp\/suag039","relation":{},"ISSN":["1520-765X","1554-2815"],"issn-type":[{"value":"1520-765X","type":"print"},{"value":"1554-2815","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,5]]},"published":{"date-parts":[[2026,3,11]]}}}